. 2021 Mar;10(3):1277–1291. doi: 10.21037/tlcr-20-1153

Table 1. The IC₅₀ values and CI for combination of EGRR-TKIs and metformin against TKI-resistant cell lines.

Cell line	TKI	TKI IC₅₀	Metformin IC₅₀	TKI IC₅₀ in combination	CI	Interpretation
PC9R	Gefitinib	9.82 μM	16.79 μM	4.67 μM	0.77	Synergism
PC9R/OR	Osimertinib	1.26 μM	13.72 μM	0.51 μM	0.77	Synergism

TKI, tyrosine kinase inhibitor; CI, combination indices.

Table 1. The IC50 values and CI for combination of EGRR-TKIs and metformin against TKI-resistant cell lines.